BioNote바이오노트
377740 · KOSPI · ₩377740 · 바이오노트
₩4,595▲ ₩40 (0.88%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | ₩118B | ₩103B | ₩90B | ₩480B |
| Cost of sales | ₩53B | ₩52B | ₩102B | ₩139B |
| Gross profit | ₩66B | ₩51B | −₩12B | ₩341B |
| Operating income | ₩17B | ₩12B | −₩47B | ₩295B |
| Net income | −₩87B | ₩55B | −₩20B | ₩308B |
| Net income to shareholders | −₩87B | ₩55B | −₩20B | ₩308B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total assets | ₩1.6T | ₩1.7T | ₩1.6T | ₩1.8T |
| Current assets | ₩407B | ₩466B | ₩456B | ₩825B |
| Cash and equivalents | ₩18B | ₩107B | ₩147B | ₩681B |
| Total liabilities | ₩45B | ₩61B | ₩36B | ₩157B |
| Current liabilities | ₩13B | ₩24B | ₩11B | ₩50B |
| Borrowings | ₩4.1B | ₩3.6B | ₩3.3B | ₩7.5B |
| Total equity | ₩1.5T | ₩1.6T | ₩1.6T | ₩1.6T |
| Shareholders' equity | ₩1.5T | ₩1.6T | ₩1.6T | ₩1.6T |
Cash flow
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash from operations | ₩14B | ₩58B | −₩4.2B | ₩249B |
| Capital spending | ₩8.1B | ₩10B | ₩4B | ₩42B |
| Free cash flow | ₩6.3B | ₩47B | −₩8.2B | ₩207B |
| Dividends paid | ₩20B | ₩20B | ₩50B | ₩50B |
Consolidated where available. Amounts in won.
Also known as: BioNote / 바이오노트 / 377740 / KRX:377740
Source: KRX statistical information